Latest Period
Q4 2025
Security Snapshot
REGENXBIO Inc. - Common Stock (RGNX) Institutional Ownership
CUSIP: 75901B107
13F Institutional Holders and Ownership History from Q3 2015 to Q1 2026
Institutions Reporting
172
Shares (Excl. Options)
41,068,451
Price
$14.40
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- RGNX on Nasdaq
- Shares outstanding
- 50,868,756
- Price per share
- $8.38
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 41,068,451
- Total reported value
- $591,295,423
- % of total 13F portfolios
- 0%
- Share change
- -634,347
- Value change
- -$5,673,459
- Number of holders
- 172
- Price from insider filings
- $8.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RGNX - REGENXBIO Inc. - Common Stock is tracked under CUSIP 75901B107.
- 172 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 172 to 53 between Q4 2025 and Q1 2026.
- Reported value moved from $591,295,423 to $63,084,230.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 172 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 75901B107?
CUSIP 75901B107 identifies RGNX - REGENXBIO Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75901B107:
Significant Owners of REGENXBIO Inc. - Common Stock (RGNX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 9.9% | $43,942,300 | 5,062,477 | Redmile Group, LLC | 30 Jun 2025 | |||
| JPMORGAN CHASE & CO | 7.4% | $34,806,291 | 3,698,862 | JPMORGAN CHASE & CO. | 31 Dec 2024 | |||
| BlackRock, Inc. | 7.3% | -34% | $34,616,925 | -$16,819,095 | 3,678,738 | -33% | BlackRock, Inc. | 31 Mar 2025 |
| STATE STREET CORP | 4.4% | $20,568,858 | 2,185,851 | STATE STREET CORPORATION | 31 Dec 2024 | |||
| BlackRock Portfolio Management LLC | 4.1% | -35% | $30,032,914 | -$15,091,042 | 2,085,619 | -33% | BlackRock Portfolio Management LLC | 31 Dec 2025 |
As of 31 Dec 2025, 172 institutional investors reported holding 41,068,451 shares of REGENXBIO Inc. - Common Stock (RGNX). This represents 81% of the company’s total 50,868,756 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of REGENXBIO Inc. - Common Stock (RGNX) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | 5,756,811 | -9.6% | 0% | $82,898,078 |
| Redmile Group, LLC | 8.6% | 4,368,804 | -6.9% | 4.6% | $62,910,778 |
| JPMORGAN CHASE & CO | 7% | 3,553,502 | -12% | 0% | $51,170,429 |
| VANGUARD GROUP INC | 6.6% | 3,374,140 | +1.1% | 0% | $48,587,616 |
| STATE STREET CORP | 4.5% | 2,286,736 | +15% | 0% | $32,928,998 |
| MORGAN STANLEY | 4% | 2,014,787 | +18% | 0% | $29,012,933 |
| GOLDMAN SACHS GROUP INC | 3.5% | 1,785,437 | -3.6% | 0% | $25,710,293 |
| AQR CAPITAL MANAGEMENT LLC | 2.7% | 1,361,962 | +5.6% | 0.01% | $19,612,253 |
| Integral Health Asset Management, LLC | 2.4% | 1,200,000 | +9.1% | 0.88% | $17,280,000 |
| Assenagon Asset Management S.A. | 2.3% | 1,160,380 | +64% | 0.03% | $16,709,472 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 1,145,206 | +1.7% | 0% | $16,495,225 |
| 22NW, LP | 1.8% | 923,679 | 0% | 10% | $13,300,978 |
| DIMENSIONAL FUND ADVISORS LP | 1.8% | 903,851 | -18% | 0% | $13,014,235 |
| Nuveen, LLC | 1.3% | 658,510 | +19% | 0% | $9,482,544 |
| Pale Fire Capital SE | 0.98% | 499,526 | +95% | 0.93% | $7,193,174 |
| Qube Research & Technologies Ltd | 0.87% | 442,690 | +55% | 0.01% | $6,374,736 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.77% | 391,461 | -0.13% | 0% | $5,637,038 |
| ACADIAN ASSET MANAGEMENT LLC | 0.74% | 375,399 | -5.9% | 0.01% | $5,404,000 |
| NORTHERN TRUST CORP | 0.73% | 373,689 | -6.8% | 0% | $5,381,121 |
| STIFEL FINANCIAL CORP | 0.66% | 335,046 | +4.6% | 0% | $4,824,676 |
| RENAISSANCE TECHNOLOGIES LLC | 0.65% | 333,086 | +7.6% | 0.01% | $4,796,438 |
| BANK OF AMERICA CORP /DE/ | 0.59% | 300,609 | -28% | 0% | $4,328,769 |
| HRT FINANCIAL LP | 0.59% | 299,915 | +74% | 0.01% | $4,318,000 |
| Voss Capital, LP | 0.58% | 295,000 | -41% | 0.23% | $4,248,000 |
| GSK plc | 0.53% | 271,456 | 0% | 0.49% | $3,908,966 |
Institutional Holders of REGENXBIO Inc. - Common Stock (RGNX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 7,532,091 | $63,084,230 | +$1,555,077 | $8.38 | 53 |
| 2025 Q4 | 41,068,451 | $591,295,423 | -$5,673,459 | $14.40 | 172 |
| 2025 Q3 | 41,358,721 | $399,176,079 | -$3,663,002 | $9.65 | 165 |
| 2025 Q2 | 42,035,725 | $345,140,942 | +$5,513,913 | $8.21 | 159 |
| 2025 Q1 | 41,667,225 | $297,962,085 | -$1,501,158 | $7.15 | 163 |
| 2024 Q4 | 42,074,510 | $325,173,475 | -$15,537,348 | $7.73 | 175 |
| 2024 Q3 | 43,665,569 | $458,056,433 | -$8,522,130 | $10.49 | 184 |
| 2024 Q2 | 43,782,930 | $512,285,979 | +$5,420,902 | $11.70 | 180 |
| 2024 Q1 | 42,534,646 | $895,831,731 | +$95,824,018 | $21.07 | 185 |
| 2023 Q4 | 38,123,027 | $684,323,807 | +$18,843,309 | $17.95 | 167 |
| 2023 Q3 | 37,072,487 | $610,280,035 | -$2,249,035 | $16.46 | 157 |
| 2023 Q2 | 37,122,782 | $742,048,193 | +$3,963,188 | $19.99 | 165 |
| 2023 Q1 | 37,009,156 | $699,776,275 | +$18,824,498 | $18.91 | 170 |
| 2022 Q4 | 35,702,552 | $809,736,875 | +$5,376,487 | $22.68 | 180 |
| 2022 Q3 | 35,093,974 | $927,284,018 | -$30,479,732 | $26.43 | 173 |
| 2022 Q2 | 36,159,183 | $893,093,296 | +$28,890,952 | $24.70 | 157 |
| 2022 Q1 | 34,902,249 | $1,157,712,999 | -$21,017,474 | $33.19 | 181 |
| 2021 Q4 | 35,507,306 | $1,160,896,124 | +$58,351,051 | $32.70 | 168 |
| 2021 Q3 | 33,398,271 | $1,400,353,918 | -$3,046,167 | $41.92 | 177 |
| 2021 Q2 | 33,460,640 | $1,299,751,931 | +$26,836,789 | $38.85 | 168 |
| 2021 Q1 | 32,853,108 | $1,120,584,466 | +$187,839,315 | $34.11 | 178 |
| 2020 Q4 | 27,329,284 | $1,239,697,831 | -$41,654,835 | $45.36 | 182 |
| 2020 Q3 | 28,512,126 | $785,403,793 | -$29,743,448 | $27.52 | 162 |
| 2020 Q2 | 29,376,827 | $1,082,072,585 | +$20,048,711 | $36.83 | 174 |
| 2020 Q1 | 28,922,545 | $936,893,202 | -$29,109,226 | $32.38 | 160 |
| 2019 Q4 | 29,584,479 | $1,212,076,877 | -$13,179,927 | $40.97 | 178 |
| 2019 Q3 | 29,248,667 | $1,041,238,768 | -$21,895,746 | $35.60 | 165 |
| 2019 Q2 | 29,447,574 | $1,510,592,208 | -$22,838,253 | $51.37 | 184 |
| 2019 Q1 | 30,143,203 | $1,727,382,727 | +$15,646,108 | $57.31 | 206 |
| 2018 Q4 | 29,941,433 | $1,255,681,603 | +$31,694,613 | $41.95 | 178 |
| 2018 Q3 | 28,543,303 | $2,154,975,590 | +$194,166,110 | $75.50 | 198 |
| 2018 Q2 | 26,028,733 | $1,867,750,691 | +$332,228,528 | $71.75 | 174 |
| 2018 Q1 | 22,371,972 | $667,791,727 | +$29,287,426 | $29.85 | 118 |
| 2017 Q4 | 21,584,761 | $717,686,392 | +$5,112,723 | $33.25 | 106 |
| 2017 Q3 | 21,399,716 | $704,035,906 | -$14,361,368 | $32.95 | 87 |
| 2017 Q2 | 22,655,785 | $447,763,347 | +$37,345,656 | $19.75 | 86 |
| 2017 Q1 | 20,796,965 | $401,380,019 | +$94,928,884 | $19.30 | 86 |
| 2016 Q4 | 18,300,126 | $339,456,250 | +$28,424,124 | $18.55 | 77 |
| 2016 Q3 | 16,939,017 | $237,123,842 | +$3,104,010 | $14.01 | 71 |
| 2016 Q2 | 17,911,156 | $143,725,600 | +$9,894,905 | $8.00 | 67 |
| 2016 Q1 | 16,627,713 | $179,564,518 | +$4,021,922 | $10.80 | 62 |
| 2015 Q4 | 15,040,714 | $247,165,923 | -$9,897,144 | $16.60 | 65 |
| 2015 Q3 | 14,305,786 | $310,215,000 | +$310,214,985 | $22.03 | 47 |